KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Acquisitions & Divestments: 2009-2024

Historic Change in Acquisitions & Divestments for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $633.0 million.

  • Biomarin Pharmaceutical's Change in Acquisitions & Divestments fell 38.55% to $98.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $449.1 million, marking a year-over-year decrease of 24.09%. This contributed to the annual value of $633.0 million for FY2024, which is 26.81% down from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Change in Acquisitions & Divestments stood at $633.0 million for FY2024, which was down 26.81% from $864.9 million recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Change in Acquisitions & Divestments ranged from a high of $864.9 million in FY2023 and a low of $555.8 million during FY2020.
  • For the 3-year period, Biomarin Pharmaceutical's Change in Acquisitions & Divestments averaged around $706.0 million, with its median value being $633.0 million (2024).
  • In the last 5 years, Biomarin Pharmaceutical's Change in Acquisitions & Divestments spiked by 39.50% in 2023 and then fell by 26.81% in 2024.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Change in Acquisitions & Divestments stood at $555.8 million in 2020, then climbed by 24.33% to $691.0 million in 2021, then decreased by 10.28% to $620.0 million in 2022, then soared by 39.50% to $864.9 million in 2023, then dropped by 26.81% to $633.0 million in 2024.